These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 22626508)

  • 1. Economic impact of combination therapy with infliximab plus azathioprine for drug-refractory Crohn's disease: a cost-effectiveness analysis.
    Saito S; Shimizu U; Nan Z; Mandai N; Yokoyama J; Terajima K; Akazawa K
    J Crohns Colitis; 2013 Mar; 7(2):167-74. PubMed ID: 22626508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strategies for the prevention of postoperative recurrence in Crohn's disease: results of a decision analysis.
    Ananthakrishnan AN; Hur C; Juillerat P; Korzenik JR
    Am J Gastroenterol; 2011 Nov; 106(11):2009-17. PubMed ID: 21788991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative cost-effectiveness of strategies to prevent postoperative clinical recurrence of Crohn's disease.
    Doherty GA; Miksad RA; Cheifetz AS; Moss AC
    Inflamm Bowel Dis; 2012 Sep; 18(9):1608-16. PubMed ID: 21905173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of top-down versus step-up strategies in patients with newly diagnosed active luminal Crohn's disease.
    Marchetti M; Liberato NL; Di Sabatino A; Corazza GR
    Eur J Health Econ; 2013 Dec; 14(6):853-61. PubMed ID: 22975794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of scheduled maintenance treatment with infliximab for pediatric Crohn's disease.
    Punekar YS; Sunderland T; Hawkins N; Lindsay J
    Value Health; 2010; 13(2):188-95. PubMed ID: 19883407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pilot study comparing hydrocortisone premedication to concomitant azathioprine treatment in preventing loss of response to infliximab.
    Mantzaris GJ; Viazis N; Petraki K; Papamichael K; Theodoropoulos I; Roussos A; Karakoidas C; Koilakou S; Raptis N; Smyrnidis A; Agalos G; Karamanolis DG
    Eur J Gastroenterol Hepatol; 2009 Sep; 21(9):1042-8. PubMed ID: 20139856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can mucosal healing be a cost-effective endpoint for biologic therapy in Crohn's disease? A decision analysis.
    Ananthakrishnan AN; Korzenik JR; Hur C
    Inflamm Bowel Dis; 2013 Jan; 19(1):37-44. PubMed ID: 22416019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simulated cost-effectiveness of a novel precision-guided dosing strategy in adult patients with Crohn's disease initiating infliximab maintenance therapy.
    Alizadeh ER; Dervieux T; Vermeire S; Dubinsky M; D'Haens G; Laharie D; Shim A; Vaughn BP
    Pharmacotherapy; 2024 Apr; 44(4):331-342. PubMed ID: 38576238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Canadian cost-utility analysis of initiation and maintenance treatment with anti-TNF-α drugs for refractory Crohn's disease.
    Blackhouse G; Assasi N; Xie F; Marshall J; Irvine EJ; Gaebel K; Campbell K; Hopkins R; O'Reilly D; Tarride JE; Goeree R
    J Crohns Colitis; 2012 Feb; 6(1):77-85. PubMed ID: 22261531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health-economic analysis: cost-effectiveness of scheduled maintenance treatment with infliximab for Crohn's disease--modelling outcomes in active luminal and fistulizing disease in adults.
    Lindsay J; Punekar YS; Morris J; Chung-Faye G
    Aliment Pharmacol Ther; 2008 Jul; 28(1):76-87. PubMed ID: 18410558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Efficacy of Infliximab Monotherapy versus Infliximab-Azathioprine Sequential Treatment in Crohn's Disease: Experience from a Tertiary Medical Center in China.
    Zhang T; Wang Z; Fan R; Zhang M; Lin Y; Hong L; Zhou X; Hu S; Cheng M; Zhong J
    Biomed Res Int; 2016; 2016():8648307. PubMed ID: 27896276
    [No Abstract]   [Full Text] [Related]  

  • 12. The Cost-effectiveness of Initial Immunomodulators or Infliximab Using Modern Optimization Strategies for Crohn's Disease in the Biosimilar Era.
    Vasudevan A; Ip F; Liew D; van Langenberg DR
    Inflamm Bowel Dis; 2020 Feb; 26(3):369-379. PubMed ID: 31532479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful use of infliximab and tacrolimus in a patient with Crohn's disease.
    Cortes X; Borrás-Blasco J; Rodríguez J; Moreno M; Molés JR; Castera E
    Int J Clin Pharmacol Ther; 2015 Aug; 53(8):692-6. PubMed ID: 25997551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of infliximab and anti-infliximab antibody measurements to evaluate and optimize efficacy and safety of infliximab maintenance therapy in Crohn's disease.
    Steenholdt C
    Dan Med J; 2013 Apr; 60(4):B4616. PubMed ID: 23651723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Azathioprine Withdrawal Is Cost-Effective in Patients with Crohn's Disease in Remission on Infliximab and Azathioprine.
    Syal G; Melmed GY; Almario CV; Spiegel BMR
    Dig Dis Sci; 2023 Feb; 68(2):404-413. PubMed ID: 36512266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-utility analysis of biologic treatments for moderate-to-severe Crohn's disease.
    Tang DH; Armstrong EP; Lee JK
    Pharmacotherapy; 2012 Jun; 32(6):515-26. PubMed ID: 22528603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infliximab, azathioprine, or combination therapy for Crohn's disease.
    Ruffolo C; Scarpa M; Bassi N
    N Engl J Med; 2010 Sep; 363(11):1086-7; author reply 1087-8. PubMed ID: 20848681
    [No Abstract]   [Full Text] [Related]  

  • 18. Cost-utility of biological treatment sequences for luminal Crohn's disease in Europe.
    Rencz F; Gulácsi L; Péntek M; Gecse KB; Dignass A; Halfvarson J; Gomollón F; Baji P; Peyrin-Biroulet L; Lakatos PL; Brodszky V
    Expert Rev Pharmacoecon Outcomes Res; 2017 Dec; 17(6):597-606. PubMed ID: 28434387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cost-effectiveness of infliximab in Crohn's disease.
    Smart C; Selinger CP
    Expert Rev Pharmacoecon Outcomes Res; 2014 Oct; 14(5):589-98. PubMed ID: 25138162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse events do not outweigh benefits of combination therapy for Crohn's disease in a decision analytic model.
    Siegel CA; Finlayson SR; Sands BE; Tosteson AN
    Clin Gastroenterol Hepatol; 2012 Jan; 10(1):46-51. PubMed ID: 21963958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.